Biogen CEO Scangos On Alzheimer's, Multiple Sclerosis – And Pricing
Executive Summary
George Scangos talks about the tradeoffs that drug pricing requires, and the logistical challenges that a blockbuster Alzheimer's product would create.
You may also be interested in...
Spotlight Returns To Biogen R&D To Sustain Success
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.
Can US FDA Share Drug Sponsor’s Information With Patent & Trademark Office?
Patent office could request information from FDA that is material to patentability, speakers at USPTO-FDA ‘listening session’ advise the agencies. Information exchange raises questions about trade secret protection and burdens on agencies.